Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

Fig. 4

Comparison of immune cell composition and the representative marker expression between paired primary lung tumors and brain metastases. (A) 11 immune cell compositions comparison by using CIBERSORT between matched primary lung tumors and brain metastases. (B) Comparison of macrophage subtypes (M0, M1, M2) between matched primary lung tumors and brain metastases. (C) Comparison of CD68 expression level between matched primary lung tumors and brain metastases. (D) Comparison of CD163 expression level between matched primary lung tumors and brain metastases. (E) Comparison of CD163/CD68 expression level ratio between matched primary lung tumors and brain metastases

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us